Among the SIRT3 activators and inhibitors introduced above, no compounds targeting SIRT3 for cancer therapy have entered clinical trials, although honokiol has been used as a therapeutic agent for non-small cell lung cancer in China, but the relationship between honokiol and its activation of SIRT3 is ambiguous, and needs to be further explored 111. The gene discussed is SIRT3; the disease is cancer.